Argenx price target lowered to $1,140 from $1,250 at Morgan Stanley
Morgan Stanley reduced its price target for Argenx (ARGX) to $1,140 from $1,250, maintaining an Overweight rating. The change follows the company's discontinuation of the Phase 3 UNITY study in Sjogren’s due to futility. The analyst views the updates as mixed for the indication but supportive of the broader investment thesis.
How this was made
The 30-second read
Why it matters
The target reduction reflects diminished expectations for near‑term revenue from the failed trial, likely pressuring the stock.
Market read
Analyst downgrade combined with trial termination creates a short‑term bearish catalyst for ARGX.
What to watch
Potential pipeline assets not discussed could offset the setback; market may be focusing too heavily on a single trial.
Background
Argenx is a Nasdaq‑listed biotech firm developing therapies for autoimmune diseases. The UNITY study in Sjögren’s syndrome was a late‑stage trial.
Ticker impact
Morgan Stanley cut Argenx's price target to $1,140 from $1,250 after the company halted its Phase 3 UNITY study for futility.
likely downside as investors price in the lower target
Target cuts are immediate catalysts; the study termination further weakens growth expectations.
Market effects
Biotech sector may see modest pressure as a peer's trial failure and target cut raise concerns about similar programs.
Limited to U.S. and European biotech investors.
Low; impact confined to Argenx and closely related biotech stocks.
Counterpoint
Some investors may view the target cut as an overreaction, seeing a buying opportunity if the study failure is isolated.
Key entities
- AnalystMorgan Stanley
Equity research firm that lowered the price target.
- CompanyArgenx
Biopharmaceutical company developing autoimmune disease treatments.
